Applied Genetic Technologies Corporation (NASDAQ:AGTC) will be hosting a conference call at 8:00 AM eastern time on 9th September 2020, to discuss its 4Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.agtc.com
Earnings Expectation
Applied Genetic Technologies Corporation is expected to report fourth quarter earnings results, before market open, on Wednesday 9th September 2020. Analysts polled by Thomson Reuters anticipate fourth quarter loss of $ 0.48 per share. Looking ahead, the full year loss are expected at $ 2.07 per share on the revenues of $ 2.55 million.
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The companys lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation.
